A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

No significant improvement seen in overall survival with addition of hormone therapy to post-radical prostatectomy radiotherapy.

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, ...

A prospective study exploring genomic correlates of clinical outcome in patients with metastatic castration-sensitive prostate cancer receiving enzalutamide. This is an ASCO Meeting Abstract from the ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Petrylak, MD, of the Yale School of Medicine notes that bone health is a frequently underappreciated aspect of care for ...

TRIM28-mediated SUMOylation of ERG at K389 and its association with cell proliferation, PARP inhibitor response, and 53BP1 expression in castration-resistant prostate cancer. Heterogeneity and ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...